Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf−/−mouse model

Genome-wide transposon screening and quantitative insertion site sequencing for cancer gene discovery in mice

(2017) Mathias J Friedrich et al.   Nature Protocols

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

(2016) Pascal Furet et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

(2016) Elizabeth C. Townsend et al.   CANCER CELL

High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells

(2016) Thomas Horn et al.   CANCER RESEARCH

Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia

(2016) T. Pandzic et al.   CLINICAL CANCER RESEARCH

Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120

(2016) S.-H. Chen et al.   Cancer Discovery

Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo

(2015) C. G. Hoffman-Luca et al.   CLINICAL CANCER RESEARCH

Sleeping Beauty transposon insertional mutagenesis based mouse models for cancer gene discovery

(2015) Branden S Moriarity et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

(2015) Philipp Holzer et al.   JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

(2015) E. Weisberg et al.   MOLECULAR CANCER THERAPEUTICS

CRISPR-Cas9–based target validation for p53-reactivating model compounds

(2015) Michael Wanzel et al.   Nature Chemical Biology

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

(2015) Hui Gao et al.   NATURE MEDICINE

Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment

(2015) C. Gianna Hoffman-Luca et al.   PLoS One

BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model

(2015) Daniele Perna et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

Recurrent turnover of senescent cells during regeneration of a complex structure

(2015) Maximina H Yun et al.   eLife

Limiting the power of p53 through the ubiquitin proteasome pathway

(2014) Vinod Pant et al.   GENES & DEVELOPMENT

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

(2014) Yujun Zhao et al.   JOURNAL OF MEDICINAL CHEMISTRY

A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer

(2014) Roland Rad et al.   NATURE GENETICS

PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors

(2014) William Lee et al.   NATURE GENETICS

Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics

(2013) Li Chen et al.   BMC CANCER

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)

(2013) Krzysztof Zak et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model

(2013) Emilie A Bard-Chapeau et al.   NATURE GENETICS

Sleeping Beauty mutagenesis in a mouse medulloblastoma model defines networks that discriminate between human molecular subgroups

(2013) L. A. Genovesi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1

(2013) L. A. Ramkissoon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of frequent BRAF copy number gain and alterations of RAF genes in chinese prostate cancer

(2012) Guoping Ren et al.   GENES CHROMOSOMES & CANCER

Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations

(2012) Trevor J. Pugh et al.   NATURE

Novel mutations target distinct subgroups of medulloblastoma

(2012) Giles Robinson et al.   NATURE

Dissecting the genomic complexity underlying medulloblastoma

(2012) David T. W. Jones et al.   NATURE

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

(2011) Genevieve Schindler et al.   ACTA NEUROPATHOLOGICA

BRAFAlterations in Primary Glial and Glioneuronal Neoplasms of the Central Nervous System With Identification of 2 Novel KIAA1549

(2011) Alex Lin et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Novel Molecular and Computational Methods Improve the Accuracy of Insertion Site Analysis in Sleeping Beauty-Induced Tumors

(2011) Benjamin T. Brett et al.   PLoS One

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

(2010) Nallasivam Palanisamy et al.   NATURE MEDICINE

PiggyBac Transposon Mutagenesis: A Tool for Cancer Gene Discovery in Mice

(2010) R. Rad et al.   SCIENCE

Chromosomal mobilization and reintegration ofSleeping BeautyandPiggyBactransposons

(2009) Qi Liang et al.   GENESIS

Cytoplasmic functions of the tumour suppressor p53

(2009) Douglas R. Green et al.   NATURE

Synergistic drug combinations tend to improve therapeutically relevant selectivity

(2009) Joseph Lehár et al.   NATURE BIOTECHNOLOGY

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Tandem Duplication Producing a Novel OncogenicBRAFFusion Gene Defines the Majority of Pilocytic Astrocytomas

(2008) David T.W. Jones et al.   CANCER RESEARCH